14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $157.65 $181.90 Wednesday, 1st May 2024 ABBV stock ended at $161.72. This is 0.566% less than the trading day before Tuesday, 30th Apr 2024. During the day the stock fluctuated 1.51% from a day low at $161.26 to a day high of $163.69.
90 days $157.65 $182.89
52 weeks $130.96 $182.89

Historical AbbVie Inc prices

Date Open High Low Close Volume
May 01, 2024 $162.09 $163.69 $161.26 $161.72 3 930 005
Apr 30, 2024 $159.59 $163.05 $159.59 $162.64 5 035 042
Apr 29, 2024 $159.59 $161.55 $158.56 $161.52 6 030 595
Apr 26, 2024 $167.09 $167.46 $157.65 $159.62 10 358 332
Apr 25, 2024 $167.66 $169.29 $165.57 $167.29 5 325 574
Apr 24, 2024 $168.59 $169.11 $166.74 $167.80 2 918 594
Apr 23, 2024 $168.59 $170.37 $168.30 $169.54 3 939 029
Apr 22, 2024 $167.68 $169.59 $166.92 $167.89 4 434 323
Apr 19, 2024 $165.02 $166.60 $163.26 $166.41 4 246 219
Apr 18, 2024 $164.96 $167.44 $164.43 $164.66 4 290 392
Apr 17, 2024 $164.15 $164.74 $163.23 $164.25 3 580 886
Apr 16, 2024 $162.18 $163.73 $162.08 $162.54 3 430 275
Apr 15, 2024 $164.52 $164.70 $161.50 $161.67 3 484 047
Apr 12, 2024 $164.45 $164.45 $160.00 $162.28 5 514 859
Apr 11, 2024 $169.20 $169.37 $167.23 $167.52 3 059 034
Apr 10, 2024 $168.59 $169.95 $167.36 $169.03 2 423 150
Apr 09, 2024 $169.73 $170.55 $167.40 $170.14 5 351 395
Apr 08, 2024 $169.21 $171.97 $168.40 $169.80 4 743 386
Apr 05, 2024 $168.00 $171.04 $167.29 $170.00 5 578 438
Apr 04, 2024 $177.65 $177.70 $167.46 $167.90 8 698 287
Apr 03, 2024 $180.72 $181.60 $176.60 $177.33 4 730 207
Apr 02, 2024 $179.39 $181.03 $178.51 $180.69 4 508 916
Apr 01, 2024 $181.88 $181.90 $179.24 $180.76 3 084 596
Mar 28, 2024 $181.00 $182.29 $180.30 $182.10 3 081 475
Mar 27, 2024 $179.80 $180.58 $178.81 $180.35 5 056 428
Click to get the best stock tips daily for free!

About AbbVie Inc

AbbVie AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia ... ABBV Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT